INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
United States Food and Drug Administration
Silver Spring, Estados UnidosPublicaciones en colaboración con investigadores/as de United States Food and Drug Administration (11)
2022
-
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
The Lancet. Haematology, Vol. 9, Núm. 5, pp. e374-e384
2021
-
Minimal residual disease in Myeloma: Application for clinical care and new drug registration
Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212
2018
-
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
The Lancet Haematology, Vol. 5, Núm. 11, pp. e563-e598
2016
-
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356
Autophagy
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, Vol. 12, Núm. 1, pp. 1-222
-
Regulation of striatal astrocytic receptor for advanced glycation end-products variants in an early stage of experimental Parkinson's disease
Journal of Neurochemistry, pp. 598-609
2014
-
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium
American Journal of Hematology
2012
-
Guidelines for the use and interpretation of assays for monitoring autophagy
Autophagy, Vol. 8, Núm. 4, pp. 445-544
2010
-
Human peripheral blood B-Cell compartments: A crossroad in B-cell traffic
Cytometry Part B - Clinical Cytometry, Vol. 78, Núm. SUPPL. 1
2007
-
ZAP70 editorial: A follow-up to the special issue
Cytometry Part B - Clinical Cytometry
2006
-
ZAP-70 in CLL: Towards standardization of a biomarker for patient management: History of clinical cytometry special issue
Cytometry Part B - Clinical Cytometry